Risk factor
Moderate default risk
Profitability factor
Very low or no dividends
About
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E
Buy
Sell